|
|
 |
|
Viewing report
|
|
|
|
Anemia Drugs - Global Strategic Business Report
Global Industry Analysts, Inc., April 2010, Pages: 490
This report analyzes the worldwide markets for Anemia Drugs in US$ Million by the following segments: Short Acting ESAs (Erythropoiesis Stimulating Agents), and Long Acting ESAs (Erythropoiesis Stimulating Agents). The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 51 companies including many key and niche players such as Acceleron Pharma, Inc., Akebia Therapeutics, Inc., Amgen, Inc., Bristol-Myers Squibb Company, Centocor Ortho Biotech Products, L.P., F. Hoffmann-La Roche Ltd., Chugai Pharmaceutical Co. Ltd., Fibrogen, Inc., GlaxoSmithKline PLC, Hospira, Inc., Novartis International AG, Pfizer, Inc., ProMetic Life Sciences, Inc., and Takeda Pharmaceutical Company Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
Customers who bought this item also bought
Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Intravenous (IV) Iron Drugs - Global Strategic Business Report
Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success
Aplastic Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success
Bipolar Disorder - Global Strategic Business Report
Bladder Cancer Therapeutics - Global Strategic Business Report
Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted
Prostate Cancer Therapeutics - Global Strategic Business Report
Chemotherapy Induced Anemia - Pipeline Review, H2 2011
|
|
|
|
